C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni
{"title":"血清CYFRA 21-1作为硬皮病相关间质性肺疾病的预后标志物","authors":"C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni","doi":"10.1136/THORAX-2018-212555.149","DOIUrl":null,"url":null,"abstract":"Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)","PeriodicalId":164956,"journal":{"name":"Guilt by association: ILD genetics and co-morbidities","volume":"123 5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease\",\"authors\":\"C. Stock, R. Hoyles, C. Daccord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, L. Mori, T. Maher, V. Kouranos, G. Margaritopoulos, P. George, P. Molyneaux, F. Chua, D. Abraham, V. Ong, C. Denton, A. Wells, E. Renzoni\",\"doi\":\"10.1136/THORAX-2018-212555.149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)\",\"PeriodicalId\":164956,\"journal\":{\"name\":\"Guilt by association: ILD genetics and co-morbidities\",\"volume\":\"123 5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Guilt by association: ILD genetics and co-morbidities\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/THORAX-2018-212555.149\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Guilt by association: ILD genetics and co-morbidities","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/THORAX-2018-212555.149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease
Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). The progression of SSc associated ILD (SSc-ILD) is highly variable. Markers predictive of progressive ILD are needed early in the disease course, to appropriately target patients at risk of developing progressive pulmonary fibrosis. CYFRA 21–1 (CYFRA) is a tumour marker expressed by type I/type II pneumocytes and respiratory bronchiolar epithelial cells, released into the blood following cell lysis. Serum levels of CYFRA were measured in both a retrospective (n=180) and a prospective (n=118) cohort of SSc patients. Retrospective cohort mean age: 49.1 (range 47.08–51.05), 77.25% female, prospective cohort age: 56.4 (54.10–58.73), 76.23% female. Median FVC% predicted and DLCO% predicted: retrospective cohort: 80.1% (IQR:67.2–95.5) and 55.5% (44.3–68.35), respectively – prospective cohort: 73.8% (57.2–87) and 39.9% (29.2–48.8), respectively. ILD was defined as the presence of fibrosis on chest imaging (chest x-ray or HRCT) and/or a forced vital capacity (FVC)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
